2024-09-07 - Analysis Report
## GILD Stock Analysis Report

**Company Overview:** Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that develops, manufactures, and markets drugs for a variety of medical conditions, including HIV, hepatitis, cancer, and inflammatory diseases.

**Performance Analysis:**

**1.  Return Rate Comparison:**
    * **GILD Cumulative Return:** 14.61%
    * **S&P 500 (VOO) Cumulative Return:** 84.86%
    * **Performance Gap:** -75.15% (Relative Gap: 15.83%)

    GILD has significantly underperformed the S&P 500 over the analyzed period. Its performance is currently at the 15.83% percentile compared to historical data, indicating a relatively weak performance against the market benchmark.

**2.  Recent Price Movement:**
    * **Closing Price:** $79.13
    * **5-Day Moving Average:** $79.17
    * **20-Day Moving Average:** $75.96
    * **60-Day Moving Average:** $72.28

    The stock price is currently trading above all moving averages, indicating a potential upward trend. However, the relatively close proximity of the price to the 5-day moving average suggests a potential short-term correction.

**3.  Technical Indicators:**
    * **RSI:** 80.61
    * **PPO:** 0.36
    * **Delta_Previous_Relative_Divergence:** -5.9 (Short-Term Downward Trend)
    * **Expected Return:** 21.27% (5-year maximum expected return)

    The RSI indicates that the stock is currently overbought, suggesting a potential for a pullback. The PPO suggests a positive momentum. The negative Delta_Previous_Relative_Divergence further supports a short-term bearish outlook. However, the expected return suggests potential for long-term growth.

**4.  Recent Earnings and Outlook:**

| Date       | EPS  | Revenue |
|------------|------|---------|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report for Q2 2024 showed a significant beat in EPS, exceeding analysts' expectations. However, revenue missed estimates. The company attributed the earnings beat to strong sales of its HIV treatments. Despite the positive earnings surprise, the missed revenue target and the overall trend of revenue decline in recent quarters raise concerns about the sustainability of growth.

**5.  Overall Analysis:**

GILD has been struggling to keep up with the market, with a significantly lower return rate compared to the S&P 500. However, recent price action suggests a possible upward trend. Technical indicators present mixed signals, with a potential for both short-term correction and long-term growth. Despite a recent earnings beat, concerns remain about the company's revenue growth trajectory. Overall, GILD remains a risky investment with both potential upside and downside risks. Investors should carefully consider the current market conditions and the company's long-term prospects before making any investment decisions.

**6.  Investment Recommendation:**

Based on the current analysis, GILD is a **HOLD** for now. The stock's mixed performance and potential for both short-term correction and long-term growth warrant further observation and analysis. Investors should closely monitor the company's future earnings reports and any changes in the market landscape before making any decisions. 
